Comparative tolerability of treatments for juvenile idiopathic arthritis

BioDrugs

Volumn 14, Issue 3, 2000, Pages 159-183

  Prieur, Anne Marie ^a   Quartier, Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; GAMMA INTERFERON; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PENICILLAMINE; PROPIONIC ACID DERIVATIVE; SALAZOSULFAPYRIDINE; TIOPRONIN; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ADOLESCENT; ALOPECIA; ARTHROPATHY; AUTOIMMUNE DISEASE; BLEEDING; BLOOD TOXICITY; BONE DISEASE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUSHINGOID SYNDROME; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HIRSUTISM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LUNG TOXICITY; MACROPHAGE ACTIVATION; NEPHROTOXICITY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; REYE SYNDROME; SIDE EFFECT; SKIN TOXICITY; STEM CELL TRANSPLANTATION; STEROID THERAPY; STOMATITIS; TERATOGENICITY; UVEITIS;

EID: 0033786428     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014030-00003     Document Type: Review

References (249)

1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-4
2. Brewer EJ, Bass J, Baum J, et al. Current proposed revision JRA criteria. Arthritis Rheum 1977; 20 Suppl.: 195-9
3. European League Against Rheumatism (EULAR). Bulletin 3: the care of rheumatic children. Nomenclature and classification of arthritis in children. Basel: National Zeitung AG. E Munthe, 1977:47-50
4. Malleson PN, Petty RE. Remodelling the pyramid: a paediatric perspective. J Rheumatol 1990; 17: 867-8
5. Wallace ÇA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990's. Rheum Dis Clin North Am 1991; 17: 891-905
6. Schaller JG. Therapy for childhood rheumatic diseases: have we been doing enough? Arthritis Rheum 1993; 36: 65-70
7. Lehman TJ. Aggressive therapy for childhood rheumatic diseases: when are immunosuppressives appropriate? Arthritis Rheum 1993; 36: 71-4
8. Cryer B, Feldman M. Cyclooxygenase-1 andcyclooxygenase-2 inhibitor selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21
9. Golden BD, Abramson SB. Selective cyclo-oxygenase-2 inhibitors. Rheum Dis Clin North Am 1999; 25 (104): 413-21
10. Walker J, Smith M, Ford-Hutchinson AW. Anti-inflammatory drugs, prostaglandins and leukocyte migration. Agents Actions 1976; 6: 602-6
11. Forest MJ, Brooks PM. Mechanisms of action of nonsteroidal anti-inflammatory drugs. Bailleres Clin Rheumatol 1988; 2: 275-94
12. Diamant-Berger MS. Du rhumatisme noueux (polyarthrite déformante) chez les enfants. Paris: Lecrosnier et Babe Libraires, Editeurs Thèse, 1891
13. Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 1978; 62 Suppl.: 867-72
14. Kauffman RE, Roberts RJ. Aspirin use and Reye syndrome. Pediatrics 1987; 79: 1049-50
15. Favara BE, Feller AC. Pauli M, et al. Contemporary classification of histiocytosis disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations: Reclassification Working Group of the Histiocyte Society. Med PediatrOncol 1997:29: 157-66
16. Prieur AM, Stephan JL. Macrophage activation syndrome in pédiatrie rheumatic diseases. Rev Rhum Engl Ed 1994; 6: 385-8
17. Baron KS, Person DA, Brewer EJ. The toxicity of non steroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol 1982; 9: 149-55
18. Mulderg AE, Linz C, Bern E, et al. Identification of non steroidal anti-inflammatory drug-induced gastro-intestinal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993; 122:647-9
19. Hermaszewski R, Hayllar J, Woo P. Gastro-intestinal damage due to anti-inflammatory drugs in children. Br J Rheumatol 1993; 32: 69-72
20. Garazian M, Berkovitch M, Kuren G, et al. Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis 1995:54:277-80
21. Levy ML, Barron KS, Echenfield J, et al. Naproxen-induced pseudoporphyria: a distinctive photodermatosis. J Pediatr 1990; 117:660-4
22. Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking non steroidal anti-inflammatory drugs. J Pediatrics 1994; 125: 819-22
23. Brooks PM. Side effects of non steroidal anti-inflammatory drugs. Med J Aust 1988; 146: 248-51
24. Fries JF, Williams C A, Bloch DA. The relative toxicity of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1991 ; 34: 1353-60
25. Grondin C, Malleson P, Petty RE. Slow-acting antirheumatic drugs in chronic arthritis. Semin Arthritis Rheum 1988; 18: 38-47
26. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993: 23: 34-6
27. Sairanen E, Laaksonen AL. The results of gold therapy in juvenile rheumatoid arthritis. Ann Paediatr Fenn 1963; 8: 105-10
28. Myers AR. Chrysotherapy in rheumatoid arthritis. Mod Treat I971;8: 761-8
29. Brewer EJ, Giannini EH, Barkley E. Gold therapy with management of juvenile rheumatoid arthritis. Arthritis Rheum 1980:23:404-11
30. Davis P. Undesirable side effects of gold salts. J Rheumatol 1979:6: 18-24
31. Silverman ED. Miller FJ III, Bernstein B, et al. Consumplion coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872-6
32. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic. hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-6
33. Jacobs JC. The hazards of gold injections in children with juvenile rheumatoid arthritis: comment on the article by Lehman. Arthritis Rheum 1993; 36: 1636
34. Husserl FE, Shuler SE. Gold nephropathy in juvenile rheumatoid arthritis. Am J Dis Child 1979; 133:51-2
35. Pegg SJ, Lang BA, Mikhail EL, et al. Fatal bronchiolitis obliterans in a patient with rheumatoid arthritis receiving chrysotherapy. J Rheumatol 1994; 21: 549-51
36. Giannini EH. Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983; 102: 138-41
37. Kvien TK, Hoyeraal HM, Sanstad B, et al. Oral gold (auranofin) in juvenile rheumatoid arthritis: a 48-week phase II study. Clin Rheumatol 1984; 3: 551-2
38. Giannini EH, Brewer EJ, Person DA, et al. Long-term auranofin therapy in patients with juvenile rheumatoid arthritis. J Rheumatol 1986; 13:768-70
39. Giannini EH, Brewer EJ, Kuzmina N, et al. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990:33:466-76
40. Deutsch HF, Morton JI. Dissociation of human serum macroglobulins. Science 1957; 125: 600-1
41. Schairer H. Stoeber E. Long term follow-up of 235 cases of juvenile rheumatoid arthritis treated with D-penicillamine. In: Munth E, editor. D-penicillamine research in rheumatoid disease. Oslo: Fabritius & Sonner, 1976: 279-81
42. Ansell BM, Hall MA. Penicillamine in chronic arthritis of childhood. J Rheumatol 1981; 8 Suppl. 7: 112-5
43. Kvien TK, Hoyeraal HM, Sanstad B. Slow-acting antirheumatic drugs in patients with juvenile rheumatoid arthritis evaluated in a randomized parallel 50-week clinical trial. J Rheumatol 1985; 12:533-9
44. Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis. Arthritis Rheum 1985; 28: 376-82
45. Brewer EJ, Giannini EH, Kuzmina N, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269-76
46. Murphy KC, Atkins CJ, Offer RC, et al. Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicillamine. Arthritis Rheum 1981; 24: 557-60
47. Swartz MO. Silver RM. D-penicillamine induced polymyositis in juvenile chronic arthritis: report of a case. J Rheumatol 1984; 11:251-2
48. Hoult JRS. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986; 32 Suppl. 1: 1-80
49. Laassila K, Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel diseases. Scand J Rheumatol 1994; 23: 338-40
50. Besnard M, Debray D, Durand P, et al. Hépatite fulminante ehe/, deux enfants traités par salazopyrine pour une maladie de Crohn. Arch Pediatr 1999; 6: 643-6
51. Caspi D, Fuchs D, Yaron M. Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis. Ann Rheum Dis 1992; 51: 275-6
52. Senturk T, Aydintug AO, Duzgun N, et al. Seizures and hepatotoxicity following sulphasalazine administration. Rheumatol Int 1997; 17: 75-7
53. Kuipers EJ, Vellenga E, De Wolf JTM, et al. Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. J Rheumatol 1992; 19: 621-2
54. Hertzberger-Ten Gate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85-8
55. McCarthy C, Coughlan R. Sulphasalazine desensitisation in patients with arthritis. Ir J Med Sei 1994; 163: 238-9
56. Kummerle-Deshner J, Danneker G. Sulphasalazine desensitizalion in a paediatric patient with juvenile chronic arthritis. Acta Paediatr 1995; 84: 952-4
57. Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986; 13: 124-5
58. Hoza J, Havelka S, Kadlecova T, et al. Sulphasalazine in the treatment of juvenile chronic arthritis. R 1990 20: 71-4
59. Amsell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of Sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991:9:201-3
60. Joos R, Veys EM, Mielants H, et al. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991: 18: 880-4
61. Gedalia A, Barash J, Press J, et al. Sulphasalazine in the treatment of pauci-articular onset juvenile chronic arthritis Clin Exp Rheumatol 1993; 12:511-4
62. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 360-6
63. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study. Arthritis Rheum 1998; 41: 808-16
64. King JS. Treatment of cystinuria with a mercaptoproprionylglycine: a preliminary report with some notes on column chromatography of mercaptans. Proc Soc Exp Biol Med 1968; 129:927-32
65. Amor B, Mery C, De Gery A. Tiopronin (N-[2-mercaptopropionyljglycine) in rheumatoid arthritis. Arthritis Rheum 1982; 25: 698-703
66. Sany J, Combe B, Verdie-Petibon D, et al. Long term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis, a propos of 140 personal cases. Rev Rhum Mal Osteoartic 1990; 57: 105-11
67. Yasuda M, Nonaka S, Wada T, et al. Additive two DMARD therapy of the patients with rheumatoid arthritis. Clin Rheumatol 1994; 13:446-54
68. Houpt JB. A rheumatologist's verdict on the safety of chloroquine versus hydroxychloroquine: liability in off-label prescribing. J Rheumatol 1999; 26: 1864-6
69. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus: a clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3: 103-8
70. Levy GD, Münz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1 207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482-6
71. Mavrikakis M, Papazoglou S. Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55: 187-9
72. Spalten DJ. Retinopathy and antimalarial drugs: the British experience. Lupus 1996; 5 Suppl. 1: S70-2
73. Pincus P. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992:21:2-15
74. Manners PJ, Ansell BM. Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 1986: 77: 99-103
75. Rooney M. Is there a disease-modifying drug for juvenile chronic arthritis? Br J Rheumatol 1992; 31: 635-41
76. Gubner R. August S, Ginsberg V. Therapeutic suppression of tissue reactivity: II. Effect of aminopterin in rheumatoid arthritis and in psoriasis. Am J Med Sei 1951; 22: 176-82
77. Jolivet J, Cowan KH. Chabner BA, et al. The pharmacology and clinical use of methotrexate. N Eng] J Med 1983; 309: 1094102
78. Barrera P, Boerbooms AMT. Demacker PNM, et al. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 1994; 33: 1017-24
79. Russell AG, Miller C. The activity of natural killer cells in patients with rheumatoid arthritis. I: the effect of drugs used in vivo. Clin Exp Rheumatol 1986; 2: 227-9
80. Olsen N. Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-85
81. Thomas R. Carroll GJ. Reduction of leukocyte and interleukin1 concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-52
82. Segal R. Caspi D, Tishler M, et al. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 914-7
83. Giannini EH, Cassidy JT, Brewer EJ. et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 34-46
84. Giannini EH, Brewer EJ, Kusmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USAUSSR double-blind, placebo-controlled trial. The Pédiatrie Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. NEnglJ Med 1992; 326: 1043-9
85. Wallace CA, Sherry DD. Preliminary report of higher dose of methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604-7
86. Reiff A, Shaham B, Wood BP, et al. High doses methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113-8
87. Albertioni F. Plato B, Seideman, et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995; 47: 507-11
88. Dupuis LL, Koren G, Silverman ED. et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995:22: 1570-3
89. Dupuis LL. Koren G. Shore A. et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17: 1469-73
90. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764-8
91. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9
92. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. JPediatr 1987; 110:788-92
93. Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate therapy in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol 1998; 16: 181-3
94. Wallace CA, Bleyer WA, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 677-81
95. Ravelli A. Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile arthritis. J Rheumatol 1993; 20: 1573-7
96. Speckmaier M, Finseiden J, Woo P, et al. Low dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989:7:647-50
97. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297-302
98. Woo P. Wilkes H, Southwood TR, et al. Low dose methotrexate is effective in extended oligoarticular arthritis hut not in systemic arthritis of children [abstract]. Arthritis Rheum 1997: 40: S47
99. Ravelli A. Viola S. Migliavacca D. et al The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 316-20
100. Harel L. Wagner-Weiner L, Poznanski A, et al. Effects of methotrexate on radiologie progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 1370-4
101. Ravelli A. Viola S, Ramenghi B. et al. Radiologie progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998; 133: 179-80
102. Weiss AH. Wallace CA. Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis J Pediatr 1998; 1.33: 266-8
103. Wallace CA. Sherry DD. Mellins AD. et al. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993:20: 118-22
104. Ravelli A, Viola S. Ramenghi B, et al. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 1995: 22: 1574-6
105. Cimaz R, Corona F. Scarazatti M. et al. Methotrexate treatment every other week in patients with juvenile chronic arthritis. BrJ Rheumatol 1996:35: 1030-1
106. Gottlieb BS, Keenan GF. Lu T. et al. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997; 100:994-7
107. Giannini EH. Cassidy JT. Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks'? Drug Saf 1993; 9: 325-39
108. Truckenbrodt H. Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986:29:801-7
109. Rose CD, Singsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990: 117: 653-9
110. Graham LD. Myones BL, Rivas-Chacon RF, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992; 120: 468-73
111. Walker AM, Punch D, Dreyer N A, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329-35
112. Kremer JM, Kaye GI. Kaye NW. et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrex ate therapy. Followup over long treatment intervals and cor-relation with clinical and laboratory variables. Arthritis Rheum 1995:38: 1194-203
113. Kremer JM. Furst DE, Weinblatt ME, et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-61
114. Ruderman EM, Crawtord JM, Maier A. et al. Histologie liver abnormalities in autopsy series of patients with rheumatoid arthritis. BrJ Rheumatol 1997; 36: 210-3
115. Kremer JM, Alarcon GS, Lightfoot RW. et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28
116. DanaoT, Stienbrunner J, Medendorp SV, etal. Methotrexate in juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1989:32: S28
117. Keim D, Ragsdale C, Heidelberger K, et al. Hepatic fibrosis with the use of methotrexate in juvenile rheumatoid arthritis. J Rheumatol 1990; 17: 846-8
118. Hafner R, Franke J, Löhrs U. Liver biopsies in juvenile chronic arthritis ( JCA) with special reference to methotrexate therapy [abstract]. Clin Exp Rheumatol 1994; 12: S124
119. Kugathasan S, Newman AJ, Dahms BB. et al. Liver biopsy findings in patients withjuvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr 1996: 128: 149-51
120. Hashkes PJ. Balistreri WF, Bove KE, et al. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999; 134: 47-52
121. Kremer JM, PhelpsCT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-45
122. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:242-54
123. Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature. J Rheumatol 1987; 14: 1164-71
124. Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. BrJ Rheumatol 1996; 35: 441-5
125. Smith GJW. The histopathology of pulmonary reactions to drugs. Clin Chest Med 1990; 11: 95-117
126. Newman ED, Harrington TM. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988; 12: 1585-6
127. Van Der Veen MJ, Dekker JJ, Dinant HJ, et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995; 22: 1766-8
128. Pelucchi A, Lomater C. Gerloni V, et al. Lung function and diffusing capacity for carbon monoxide in patients withjuvenile chronic arthritis: effect of disease activity and low dose methotrexate. Clin Exp Rheumatol 1994; 12: 675-9
129. Camiciottoli G, Trapani S. Castellani W, et al. Effect on lung function of methotrexate and non-steroida! anti-inflammatory drugs in children with juvenile rheumatoid arthritis. Rheumatol Int 1998; 18: 11-6
130. Cron R, Sherry DD. Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998; 132: 901-2
131. Seideman P. Müller-Suur R. Renal effect of aspirin and lowdose methotrexate in rheumatoid arthritis. J Rheumatol 1993: 20: 1126-8
132. Muzaffer MA, Schneider R, Cameron BJ, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1996; 128: 698-700
133. Falcini F, Taccetti G, Ermini M, et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 175-8
134. Al-Awadhi A, Dale P, McKendry RJR. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 1993; 20: 1121-5
135. Carpenter MT, West SO, Vogelgesant SA, et al. Postoperative joint infections in rheumatoid patients on methotrexate therapy. Orthopedics 1991; 19: 207-10
136. Bridges Jr SL, Lopez-Mendez A, Han KH, et al. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991; 18: 984-8
137. Perhala RS, Wilke WS, Clough JD, et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991; 34: 146-52
138. Sany J, Anaya JM, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1129-32
139. Journeau P, Mabesoone F, Touzet Ph, et al. Total hip prosthesis for chronic juvenile arthritis. A review of a series of 34 prostheses. Rev Chir Irthop Réparatrice Appar Mot 1996; 82: 508-21
140. Wheeler DL, Vander Griend RA, Wronski TJ, et al. The shortand long-term effects of methotrexate on the rat skeleton. Bone 1995; 16:215-21
141. Preston SJ, Diamond T, Scott A, et al. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52: 582-5
142. Blanchi ML, Cimaz R, Galbiati E, et al. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporos Int 1999; 10: 20-5
143. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed 1998; 65: 267-73
144. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 146-58
145. Georgescu L, Paget SA. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf 1999; 20: 475-87
146. Padeh S, Sharon N, Schiby G, et al. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997; 24: 2035-7
147. Krugman J, Sailer-Hock M, Muller T, et al. Epstein-Barr virusassociated Hodgkin's lymphoma and Legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporin A. Hum Pathol 2000; 31: 253-5
148. Blackburn WD, Alarcon OS. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1989;32: 1341-2
149. Segal AM, Kozlowski RD, Steinbrunner JV, et al. Outcome of first trimester exposure to low-dose methotrexate (MTX) in eight pregnant rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1987; 30: S59
150. Buckley LM, Bullaboy CA, Leichman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971-3
151. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J Rheumatol 1998; 25: 36-43
152. Suzuki Y, Uehara R, Tajima C, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 1999; 28: 273-81
153. Modesto C, Castro L. Folinic acid supplementation in patients with juvenile rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 403-4
154. Alarcon GS, Morgan SL. Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 2184-5
155. Hunt PC, Rose CD, Mcllvain Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. J Rheumatol 1997; 24: 2230-2
156. Ravelli A, Migliavacca D, Viola S, et al. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 625-7
157. Prieur AM, Balafrej M, Priscelli C, et al. Traitement par le immunosuppresseurs des rhumatismes inflammatoires chroniques de l'enfant. Arch Fr Pediatr 1977; 34: 783-7
158. Prieur AM, Balafrej M, Griscelli C, et al. Résultats et risques à long terme des traitements immunosuppresseurs dans l'arthrite chronique juvénile àpropos de 40 observations. Rev Rhum 1979:46:85-90
159. Palmer RG, Dore CJ, Denman AM. Chlorambucil induced chromosome damage to human lymphocytes is dose dependent and cumulative. Lancet 1984; I: 246-9
160. Palmer RG, Ansell BM. Acute leukemia related to chlorambucil therapy in juvenile chronic arthritis. Clin Exp Rheumatol 1984; 2: 81-5
161. Kauppi MJ, Savoilanen HA, Anttila VJ, et al. Increased risk of leukemia in patients with JCA treated with chlorambucil. Acta Pediatr 1996; 85: 248-50
162. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92: 299-303
163. Deschenes G, Prieur AM, Hayem F, et al. Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 1990; 4: 463-9
164. Woo P. Complications of juvenile arthritis. An overview including amyloidosis. In: Woo P, White PH, Ansell BM, editors. Paediatric rheumatology update. Oxford: Oxford University Press, 1990: 38-46
165. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26: 898-903
166. Ansell BM. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis). J Rheumatol 1999; 26: 765-6
167. Davis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow up study. Arthritis Rheum 1995; 38: 1120-7
168. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243-7
169. Shaikov AV. Maximov AA, Speransky AI, et al. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a long term study. J Rheumatol 1992; 19: 612-6
170. Wallace C A. Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852-5
171. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737-41
172. Bogdanovic R, Banicevic M, Cvoric A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long term follow up study. Pediatr Nephrol 1990; 4:451-4
173. Dale I. The treatment of juvenile rheumatoid arthritis with azathioprine. Scand J Rheumatol 1972; 1: 125-7
174. Kvien TR, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind study. J Rheumatol 1986; 13: 118-23
175. Savoilainen HA, Kautianen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a long term follow up study. J Rheumatol 1997; 24: 2444-50
176. Fathman GG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992; 326: 1693-5
177. Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol 1988; 15: 1536-8
178. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11: 203-8
179. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436-43
180. Scholte T, Dannecker G, Thiel HJ, et al. Cyclosporin A in therapy of chronic uveitis in childhood. Ophthalmology 1996; 93: 745-8
181. Kotaniemi K. Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporin A and methotrexate. Clin Exp Rheumatol 1998; 16: 469-71
182. Kilmartin DJ. Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998:82:737-42
183. Ravelli A, De Benedetti F, Viola S, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-8
184. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporin A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750-4
185. Miller III JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989-94
186. Job-Deslandre C, Menkes CJ. Administration of methylprednisolone pulse in chronic arthritis in children. Clin Exp Rheumatol 1991;9Suppl. 6: 95-8
187. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998; 37: 1240-2
188. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids adverse reactions are more variable than expected in children. J Rheumatol 1998; 25: 1995-2002
189. Rimza ME. Complications of corticosteroid therapy. Am J Dis Child 1978; 132: 806-10
190. Garber EK, Fan PT, Bluestone R. Realistic guidelines of corticosteroid therapy in rheumatic diseases. Semin Arthritis Rheum 1981; 11:231-56
191. Byron MA. Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983: 76: 452-7
192. Svantesson H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 1994; 9 Suppl. 6: 47-50
193. Davies UM. Rooney M, Preece MA, et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994; 21: 153-8
194. Touati G, Prieur AM, Ruiz JC, et al. Beneficial effects of oneyear growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy: 1. Effects on growth velocity and body composition. J Endocrinol Metab 1998; 83: 403-9
195. Rooney M. Davies U, Ansell BM, et al. The recombinant growth hormone (rGH) study in juvenile chronic arthritis (JCA) five years on [abstract]. Clin
196. Davies UM, Jones J, Reeve J, et al. Juvenile rheumatoid arthritis: effect on disease activity and recombinant human growth hormone on insulin-like growth factor-1, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum 1997; 40: 332-40
197. Reed AM, Haugen M, Pachman LM, et al. Repair of osteoporosis in children with juvenile rheumatoid arthritis. J Pediatr 1993; 122:693-6
198. Wardy B, Linsley C, Robinson R. The effects of nutritional supplementation on bone mineral status of children with rheumatic diseases on corticosteroid therapy [abstract]. Arthritis Rheum 1989; 32: S29
199. Markham A, Bryson HM. Deflazacort: a review of its pharmacological properties and therapeutic efficacy. Drugs 1995; 50: 317-33
200. Schoemaker LR. Expanding role of biphosphonate therapy in children. J Pediatr 1999; 134: 264-7
201. GattinaraM.GallazziM.Gerloni V, etal. Use of cyclic etidronate in patients with juvenile chronic rheumatic diseases on long-term treatment with steroids [abstract). Arthritis Rheum 1998:41:545
202. Lepore L. Pennesi M, Barbi E, et al. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9 Suppl. 6: 33-5
203. Bembi B, Parma A. Bottera H, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-5
204. Glorieux F, Boshop N, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52
205. Brumsen C, Hamdy NA. Papapoulos SE. Long term effects of biphosphonate on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997; 76: 266-83
206. Liens D, Delmas PD, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953-4
207. Van Persijn Van Meerten EL, Kroon HM, Papapoulos SE. Epiand metaphyseal changes in children caused by administration of biphosphonates. Radiology 1992; 184: 249-54
208. Lteif AN, Zimmerman D. Biphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102: 990-3
209. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reaction. Am J Ophthalmol 1994; 118: 220-4
210. Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992:26: 1262-9
211. Bounameaux HM, Schifferli J, Montani JP, et al. Renal failure associated with intravenous diphosphonates (letter]. Lancet 1983; I: 471
212. Lufkin AL, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognised problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-2
213. Dollfus H. Eye involvement in children's rheumatic diseases. Baillieres Clin Rheumatol 1998; 12:309-28
214. Barley A. Cuttica R, McCullough C, et al. Triamcinolone hexacetonide into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988:6: 153-5
215. Eich GF, Halle F. Hodler J, et al. Juvenile chronic arthritis: imaging of the knees and hips before and after steroid injection. Pediatr Radiol 1994; 24: 558-63
216. Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42: 2330-4
217. Pugh MT, Grosse R, Southwood TR. Multiple joint corticosteroid injections in polyarticular juvenile arthritis: a singleblind one year follow-up study [abstract]. Arthritis Rheum 1995; 38: S283
218. Job Deslandre C, Menkes CJ. Complications of intraarticular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8: 413-6
219. Prieur AM. Management in rheumatology. In: Klippel JH. Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby. 1998:5-21.1-8
220. Huppertz HI, Pfuller H. Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 1997; 24: 1833-7
221. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999:340:227-8
222. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous immunoglobulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015-22
223. Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin in the treatment of systemic juvenile chronic arthritis. Clin Exp Rheumatol 1990; 8: 603-9
224. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol 1994:21:2353-8
225. Uziel Y. Laxer RM, Schneider R. et al. IVIG therapy in systemic onset juvenile rheumatoid arthritis: a follow up study. J Rheumatol 1996; 23: 910-8
226. Giannini EH, the Pédiatrie Rheumatology Study Group. IVIG in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 1996; 23: 919-24
227. Prieur AM. IVIG in Still's disease: still unproven, still controversial. J Rheumatol 1996; 23: 797-800
228. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995:88:211-20
229. Grom AA, Murray KJ, Luyrink L. et al. Patterns of expression of tumor necrosis factor a. Tumor necrosis factor , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-10
230. De Benedetti F. Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25: 203-6
231. Pernice W, Schuchmann L, Dippel J, et al. Therapy for systemic juvenile rheumatoid arthritis with gamma-interferon: a pilot study of nine patients. Arthritis Rheum 1989; 32: 643-6
232. Elliott MJ, Maini RN, Feldman M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
233. Maini RM, Breedveld FC. Kalden JR. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998: 41: 1552-63
234. Elliott MJ, Woo P. Charles P, et al. Suppression of fever and the acute phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factoralpha (cA2). Br J Rheumatol 1997; 36: 389-93
235. Garrison L. McDonnel ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58 Suppl. I: 165-9
236. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular rheumatoid arthritis. N Engl J Med 2000; 342: 763-9
237. Lovell DJ, Giannini EH, Lange M. et al. Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course JRA [abstract]. Arthritis Rheum 1999; 42: S117
238. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999; 59 Suppl. I: 196-8
239. St Clair EW. Interleukin 10 treatment for rheumatoid arthritis. Ann Rheum Dis 1999; 59 Suppl. II: 199-102
240. Maini RM. Taylor PC, Paleolog E, et al. Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 59 Suppl. I: 156-60
241. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16
242. Wicks I, Cooley H. Szer J. Autologous hemopoietic stem cell transplantation: a possible cure for rheumatoid arthritis? Arthritis Rheum 1997; 40: 1005-11
243. Lowenthal RM. Cohen ML, Atkinson K, et al. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993:20: 137-40
244. Slavin S. Treatment of life threatening autoimmune diseases with myeloahlative doses of immunosuppressive agents: experimental background and rationale for a BMT. Bone Marrow Transpl 1992:9: 85-8
245. Tyndall A. Grathohl A. Bone marrow transplantation in the treatment of autoimmune diseases. Br J Rheumatol 1997: 36: 1-5
246. Wulfl'raat N, Van Royen A, Bierings M, et al. Autologous haematopoietic stem-cell transplantation in four refractory juvenile chronic arthritis. Lancet 1999; 353: 550-3
247. Martini A, Maccario R. Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 1999: 42: 807-11
248. Quartier P. Prieur AM, Fischer A. Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet 1999; 353: 1885-6
249. Hagsmaa CJ. Van Piel PL. Combination of second-line antirheumatic drugs. Ann Med 1997: 29: 129-73